Figure 3. AT1 antagonist inhibits Ang II priming of PGE₂.

(A) Representative wire myography trace of femoral arterial rings primed with 1 nM Ang II, followed by addition of 100 nM PGE₂. (B) Representative trace of femoral artery with 30 minutes pretreatment with 1 μM losartan followed by addition of 1 nM Ang II priming of 100 nM PGE₂. (C) Comparison between femoral arterial ring responses to 100 nM PGE₂ with and without 1 nM Ang II priming, as well as with priming in the presence of an AT1 (losartan) or AT2 antagonist (PD123319) (N = 5). (D) Competition binding in wildtype mouse kidney membranes; displacement of [³H]PGE₂ by the EP3 agonist sulprostone, losartan, and PD123319. Graph is normalized to competition binding with cold PGE₂. (N = 3). * = P < 0.05